Health Economics›Nasopharyngeal carcinoma›Maintenance after first-line therapy

Maintenance after first-line therapy

Nasopharyngeal carcinoma · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Capecitabine monotherapy Variant #17	—	R 2 219	21d	35.9 mo	—	53	R 117 626 PFS proxy	1
Observation Partial	—	—	—	8.2 mo	—	—	—	1

2 of 2 regimens shown